Biogen Inc. BIIB
Set alert
As of Nov 3, 12:37 PM ET
- YTD
- +42.29%
- 1 year
- +65.35%
- Open
- 246.89
- Prev close
- 249.01
- Mkt cap
- 37.02B
- Vol
- 423.19K
- Avg vol
- 1.05M
- EPS
- 2.31
- P/E
- 108.40
- Div yield
- 0.00%
More statistics
- Low
- 246.25
- High
- 253.14
- Forward P/E
- 15.29
- Beta
- 0.09
- Short ratio
- 4.46
- Inst. own
- 99.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 5, 2027
- 50-d avg
- 227.08
- 200-d avg
- 201.18
- 1y target
- 264.23
1D chart
Signals (33)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | 12:36 PM | 3 minutes ago |
| MACD: Sell Signal | 12:35 PM | 4 minutes ago |
| MACD: Buy Signal | 12:26 PM | 13 minutes ago |
| SMA: Bearish | 12:00 PM | 39 minutes ago |
| SMA: Bearish | 12:00 PM | 39 minutes ago |
| MACD: Sell Signal | 12:00 PM | 39 minutes ago |
| RSI: Overbought | 11:52 AM | 47 minutes ago |
| MACD: Buy Signal | 11:45 AM | 54 minutes ago |
| SMA: Bullish | 11:39 AM | 1 hour ago |
| SMA: Bearish | 11:35 AM | 1 hour ago |
| SMA: Bearish | 11:35 AM | 1 hour ago |
| MACD: Sell Signal | 11:31 AM | 1 hour ago |
| MACD: Buy Signal | 11:28 AM | 1 hour ago |
| RSI: Overbought | 11:24 AM | 1 hour ago |
| MACD: Sell Signal | 11:19 AM | 1 hour ago |
| RSI: Overbought | 11:13 AM | 1 hour ago |
| MACD: Buy Signal | 11:09 AM | 1 hour ago |
| MACD: Sell Signal | 10:59 AM | 1 hour ago |
| SMA: Bullish | 10:43 AM | 1 hour ago |
| SMA: Bullish | 10:43 AM | 1 hour ago |
Newest 20 of 33.
Key statistics
- Market cap
- 36.81B
- Enterprise value
- 43.99B
- Trailing P/E
- 107.80
- Forward P/E
- 15.29
- PEG ratio
- 2.61
- Price / sales
- 3.57
- Price / book
- 1.95
- EPS (TTM)
- 2.31
- Beta
- 0.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 3.38%
- Revenue (TTM)
- 10.30B
- Revenue growth
- 10.60%
- Free cash flow
- 808.12M
- Total cash
- 1.30B
- Total debt
- 7.80B
- Return on equity
- 1.87%
- Shares outstanding
- 147.82M
- Short % of float
- 4.15%
- 50-day average
- 227.08
- 200-day average
- 201.18
Analyst view
Consensus: buy
- Target (low)
- 175.00
- Target (mean)
- 264.23
- Target (high)
- 325.00
- Strong buy4
- Buy21
- Hold10
- Sell1
- Strong sell0
Next earnings
Feb 5, 2027
Expected Feb 5, 2027. Consensus EPS estimate 2.85.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 5, 2027 | Dec 30, 2026 | 2.85 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 1.99 | 2.62 | +0.63 | +31.66% |
| Jul 29, 2026 | Jun 30, 2026 | 2.94 | 3.60 | +0.66 | +22.45% |
| Apr 29, 2026 | Mar 31, 2026 | 3.05 | 3.57 | +0.52 | +17.05% |
| Feb 6, 2026 | Dec 31, 2025 | 1.63 | 1.99 | +0.36 | +22.09% |
| Oct 30, 2025 | Sep 30, 2025 | 3.88 | 4.81 | +0.93 | +23.97% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Guggenheim | main | Buy | Buy |
| Nov 2, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 29, 2026 | Argus Research | up | Hold | Buy |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 29, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- biogen.com
News
- Guggenheim Maintains Buy on Biogen, Raises Price Target to $300
- Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
- HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270
- Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
- Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272
- Argus Research Upgrades Biogen to Buy, Announces $280 Price Target
- RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272
- Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $238
- TD Cowen Maintains Buy on Biogen, Raises Price Target to $260
- Wedbush Maintains Neutral on Biogen, Raises Price Target to $225
Your note
Sign in to keep a note on BIIB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEXANDER SUSAN H | Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 61,889 |
| DORSA CAROLINE D | Director | Stock Award(Grant) | Jun 16, 2025 | 31,002 |
| GREGORY GINGER | Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 22,358 |
| KRAMER ROBIN C. | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 11,471 |
| MANTAS JESUS B | Director | Stock Award(Grant) | Jun 8, 2026 | 11,263 |
| MCDONNELL MICHAEL R | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 9, 2025 | 24,341 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.32% | 18,217,239 | 4.54B | Jun 29, 2026 |
| Blackrock Inc. | 10.81% | 15,985,736 | 3.98B | Jun 29, 2026 |
| Primecap Management Company | 10.25% | 15,154,606 | 3.77B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 9,651,117 | 2.40B | Jun 29, 2026 |
| State Street Corporation | 4.97% | 7,344,327 | 1.83B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.47% | 6,604,936 | 1.64B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 5.66% | 8,359,880 | 2.08B | Jun 29, 2026 |
| Fidelity Contrafund | 3.26% | 4,817,040 | 1.20B | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 4,687,985 | 1.17B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 3,827,862 | 953.18M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.16% | 3,199,078 | 796.60M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.86% | 2,745,486 | 683.65M | Jul 30, 2026 |